Polycyclic Kinase Inhibitors for CDK/TRK Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted therapies for cancer, particularly those targeting CDK and TRK kinases, face issues with drug resistance and rapid cancer cell growth, necessitating the development of new kinase inhibitors to effectively manage these kinases.
Innovation Solution
A novel class of polycyclic compounds is developed as inhibitors for CDK and TRK kinases, including CDK2, CDK4/6, CDK9, and TRK, which are synthesized through specific chemical reactions and can be administered in pharmaceutical compositions to modulate kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional targeted therapies targeting CDK and TRK kinases are used, then initial therapeutic effect is achieved, but drug resistance develops and cancer cells grow rapidly
Solution Approach 1:
The patent modifies the chemical structure parameters of kinase inhibitors by introducing novel polycyclic heteroaryl groups and specific substituent patterns (formula I structure with variables X, R, G, p, m, n, R1, R2, R3, R4, Rf). This structural parameter change creates new compounds with improved binding affinity and resistance to drug resistance mechanisms, allowing the therapeutic agent to maintain effectiveness against both sensitive and resistant cancer cells.
Solution Approach 2:
The invention combines multiple functional moieties into a composite kinase inhibitor molecule (formula I) that integrates heteroaryl groups, linking moieties, and variable substituents. This composite structure enables the compound to interact with multiple residues in the kinase binding pocket, creating a more robust inhibitor that can overcome resistance mechanisms that would affect simpler structures.
2Object-affected harmful factors
If CDK kinase activity is inhibited to block cell cycle progression, then tumor proliferation is suppressed, but normal cell division may be affected
Solution Approach 1:
The patent employs local quality by designing the kinase inhibitor (formula I) with specific functional groups positioned to interact with particular residues in the ATP binding pocket of CDK and TRK kinases. The heteroaryl group (G) and its substituents (Rf) are positioned to form specific hydrogen bonds and hydrophobic interactions with kinase residues, creating localized binding that enhances selectivity for pathological kinases over normal cellular kinases, thereby reducing off-target effects on normal cell division.
Data Source
AI summary
The present invention provides a class of compounds containing tricyclic heteroaryl groups. Specifically, the present invention provides compounds of the structure represented by the following formula (I) (the definition of each group is described in the specification), pharmaceutical compositions containing the compounds of formula (I), as well as optical isomers, pharmaceutical acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates, etc. The compounds of formula (I) can effectively inhibit protein kinases including CDK and/or TRK, thereby playing a role in the treatment of various tumors and related disease.